A Novel Multi-Tiered Hybrid Virtual Screening Pipeline for the Discovery of WDR5-MLL1 Interaction Disruptors in

Anwar Abuelrub1,2,3, Ismail Erol1,4, Serdar Durdağı1,2,5

  • 1Laboratory for Innovative Drugs (Lab4IND), Computational Drug Design Center (HİTMER), Bahçeşehir University, İstanbul 34734, Türkiye.

ACS Omega
|October 20, 2025
PubMed

Insights

Researchers identified novel small-molecule inhibitors targeting the WDR5-MLL1 complex, crucial for epigenetic regulation and implicated in leukemia. These compounds show promise for developing new targeted therapies for MLL-rearranged leukemia and other cancers.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • WD Repeat-containing protein 5 (WDR5) is a key component of the mixed lineage leukemia (MLL) complex, vital for epigenetic regulation and linked to various cancers, especially leukemia.
  • Overexpression of WDR5 correlates with poor prognosis and increased proliferation in malignant tissues.
  • The WDR5-MLL1 interaction is essential for the MLL complex's methyltransferase activity, making the WIN site a promising therapeutic target for MLL-rearranged leukemia.

Purpose of the Study:

  • To investigate the structural dynamics of the WDR5-MLL1 complex.
  • To identify potential small-molecule inhibitors targeting the WIN site of the WDR5-MLL1 complex.
  • To develop novel therapeutic strategies for leukemia and other cancers involving WDR5 dysregulation.

Main Methods:

  • Screening of approximately one million compounds from diverse chemical libraries (ChemDiv, Enamine, Specs).
  • All-atom molecular dynamics (MD) simulations to assess ligand-receptor interactions and binding affinities (MM-GBSA).
  • Steered molecular dynamics (sMD) simulations to evaluate the stability of top-compound-receptor interactions; novel compound generation using BRICS fragmentation and Monte Carlo tree search.

Main Results:

  • Identification of several compounds, including Z88418521 and Z116334910, with superior predicted binding affinities compared to the reference molecule IA9.
  • Demonstration of competitive and allosteric modulation of the WDR5-MLL1 complex by the identified compounds.
  • Detailed analysis of WDR5-MLL1 interactions, conformational changes, and binding mechanisms, providing insights into inhibitory strategies.

Conclusions:

  • The study provides crucial mechanistic insights into the inhibition of the WDR5-MLL1 complex.
  • Identified compounds offer a strong foundation for developing targeted therapies for MLL-rearranged leukemia.
  • The distinct binding characteristics and conformational dynamics of these compounds pave the way for future experimental leukemia interventions.